EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
PROVIDENCE, R.I., May 28, 2025 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity assessment for biologic therapeutics and vaccines, is pleased to announce the appointment of Vibha Jawa, PhD, FAAPS as Chief Scientific Officer. Dr....
The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies
PROVIDENCE, R.I., April 21, 2025 /PRNewswire/ -- EpiVax, Inc. announces a new study published in Frontiers in Immunology unveiling the impact of peptides known as "Tregitopes" on antibody maturation during immune response. Lymph nodes contain...
EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements
PROVIDENCE, R.I., Feb. 27, 2025 /PRNewswire/ -- EpiVax, Inc. proudly announces the appointment of Guilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax's immunoinformatics team in 2014 and spearheaded the development of a new...
EpiVax Drives Immunogenicity Innovation in 2024: Year in Review
PROVIDENCE, R.I., Dec. 7, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and...